My watch list  

21 Current news about the topic pegylation


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Tethered nanoparticles make tumor cells more vulnerable


MIT researchers have devised a way to make tumor cells more susceptible to certain types of cancer treatment by coating the cells with nanoparticles before delivering drugs. By tethering hundreds of tiny particles to the surfaces of tumor cells in the presence of a mechanical force, the ...


image description
Direct radiolabeling of nanomaterials


Positron emission tomography plays a pivotal role for monitoring the distribution and accumulation of radiolabeled nanomaterials in living subjects. The radioactive metals are usually connected to the nanomaterial through an anchor, a so-called chelator, but this chemical binding can be omitted ...


image description
Drug delivery modification sidesteps allergic responses


Biomedical engineers at Duke University have reconfigured a popular drug-delivery technology to evade immune responses that have halted some clinical trials. Polyethylene glycol, commonly known as PEG, is a polymer commonly found in commercial products from toothpaste to cosmetics, and also in ...


image description
Stealth effect of nanocarriers for drug delivery vehicles conferred more efficiently


Scientists of the University Medical Center of the Johannes Gutenberg University Mainz and of the Max Planck Institute for Polymer Research (MPI-P) decipher stealth effect of nanocarriers evading clearance by the immune system. By using drug delivery vehicles, so-called nanocarriers, ...


celares GmbH establishes collaboration with NOF


NOF CORPORATION and celares GmbH, Germany have established strategic collaboration in the field of PEGylation. The collaboration will enable NOF CORPORATION to strengthen its position in an increasingly competitive market for Activated PEG supply. Collaboration of celares with NOF means a ...


PolyTherics is granted a further patent for its TheraPEG PEGylation technology


PolyTherics Limited announced that a further patent has been issued by the US Patent Office for TheraPEG™, PolyTherics’ proprietary method of improving the pharmacokinetic properties of proteins and peptides. The patent consolidates PolyTherics’ TheraPEG™ patent portfolio, which covers proteins ...


celares GmbH brings GMP-production facility into operation


The Berlin drug delivery company celares GmbH has brought a GMP production facility for the synthesis of activated PEG-reagents into operation in September. The company now belongs to a handful of worldwide suppliers that is capable of producing these special reagents in the required quality for ...


PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome


PolyTherics Limited announced a new collaboration with Professor Anisur Rahman at UCL (University College London), to use its proprietary site-specific PEGylation to develop a treatment for antiphospholipid syndrome. Professor Rahman and his team have been awarded a 5-year grant of nearly ...


PolyTherics moves lead candidate into development and manufacturing with DSM BioSolutions


DSM BioSolutions, DSM’s microbial fermentation CMO business unit and PolyTherics Limited announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN alpha-2a. PolyTherics has applied its HiPEG™ site-specific ...


PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company


PolyTherics Limited announced a research and option agreement with one of the world’s top ten pharmaceutical companies. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to its collaborator. The study will utilise PolyTherics’ ...


Page 1 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE